Merck & Co., announced a sales team restructure in the United States and said it will cut 1,800 sales positions. The company also plans to add 960 jobs to a new chronic care sales force, according to a Reuters article.
Merck spokeswoman Claire Gillespie said three U.S. sales teams will be cut: primary care, disease-focused endocrinology and hospital chronic care. She added the goal was “to better support changes in our business in the United States.”
The article explained the new chronic care team will focus on diabetes drug Januvia, other primary care products such as sleep medication Belsomra, and products for respiratory conditions and women’s health.
Read the full article